Skip to main content

Table 3 Comparison of weighted kaplan meier rates for HbA1c, weight, and blood pressure outcomes between CANA and DPP-4 cohortsa

From: Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors

Outcome

Number of Patients, n

Mean Baseline Value

Weighted KM Rates

3 Months

6 Months

9 Months

12 Months

18 Months

24 Months

HbA1c < 7% Among < 65 Years Old Patientsb

 CANA Cohort

7,771

8.92

%

5.67%

19.57%

26.63%

31.39%

38.37%

42.22%

 DPP-4 Cohort

8,332

8.93

%

5.31%

16.04%

22.08%

26.49%

33.14%

38.74%

 Log-Rank Test

   

0.364

<0.001*

<0.001*

<0.001*

<0.001*

<0.001*

HbA1c < 8% Among ≥ 65 Years Old Patientsc

 CANA Cohort

1,951

9.20

%

12.04%

37.52%

47.44%

52.74%

60.77%

63.54%

 DPP-4 Cohort

1,980

9.18

%

14.37%

35.35%

45.24%

50.98%

58.93%

65.27%

 Log-Rank Test

   

0.049*

0.511

0.479

0.500

0.416

0.591

HbA1c < 7%b

 CANA Cohort

11,427

8.75

%

5.65%

18.46%

25.44%

30.75%

38.21%

42.82%

 DPP-4 Cohort

12,024

8.76

%

5.80%

17.18%

23.26%

27.82%

34.67%

40.30%

 Log-Rank Test

   

0.589

0.041*

0.004*

<0.001*

<0.001*

<0.001*

HbA1c < 8%c

 CANA Cohort

7,124

9.53

%

12.18%

35.40%

45.25%

50.61%

59.21%

63.69%

 DPP-4 Cohort

7,523

9.54

%

12.04%

30.97%

39.55%

44.81%

53.39%

59.98%

 Log-Rank Test

   

0.692

<0.001*

<0.001*

<0.001*

<0.001*

<0.001*

BW Loss ≥ 5%d

 CANA Cohort

13,661

226.14

lb

6.24%

18.91%

29.23%

36.69%

47.92%

55.24%

 DPP-4 Cohort

14,410

224.41

lb

4.52%

12.46%

19.29%

25.21%

36.36%

46.17%

 Log-Rank Test

   

<0.001*

<0.001*

<0.001*

<0.001*

<0.001*

<0.001*

Systolic BP < 140 mmHge

 CANA Cohort

3,670

150.04

mmHg

40.73%

70.73%

80.89%

87.78%

92.69%

94.34%

 DPP-4 Cohort

3,738

150.13

mmHg

41.69%

67.10%

77.78%

83.91%

91.55%

94.53%

 Log-Rank Test

   

0.233

0.056

0.022*

0.005*

0.007*

0.009*

Diastolic BP < 90 mmHgf

 CANA Cohort

1,501

94.26

mmHg

47.02%

72.07%

83.84%

89.57%

94.12%

94.78%

 DPP-4 Cohort

1,600

94.25

mmHg

49.85%

74.34%

84.00%

89.67%

94.89%

98.14%

 Log-Rank Test

   

0.087

0.141

0.364

0.401

0.373

0.259

  1. BP Blood pressure, BW Body weight, CANA Canagliflozin, DPP-4 Dipeptidyl-peptidase-4, KM Kaplan Meier
  2. Note:
  3. * Significant at the 5% level
  4. aBased on the IPTW-weighted population
  5. bEvaluated among patients with a baseline HbA1c ≥7%
  6. cEvaluated among patients with a baseline HbA1c ≥8%
  7. dEvaluated among patients with a baseline BW measurement
  8. eEvaluated among patients with a baseline systolic BP ≥140 mmHg
  9. fEvaluated among patients with a baseline diastolic BP ≥90 mmHg
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us